Clarifi ASD, an emerging biotech firm and team of researchers out of SUNY Upstate Medical University and Penn State College of Medicine, discovered that children with autism have a unique epigenetic signature compared to those who are considered Neurotypical.
This testing method works by analyzing the saliva of children who are suspected of having ASD.
The average age of an ASD diagnosis comes between the ages of 4 to 5 years old; however, studies show that an even earlier diagnosis could greatly improve the long-term trajectory of a child with autism and maximize their quality of life.
“The Clarifi ASD test is designed to identify children with a high likelihood of having autism, as part of a well-child visit, in order to begin effective interventions much earlier than 4 years of age.
Research shows that these support services and therapies can make a powerful impact on long-term outcomes for children with autism, especially when applied before the age of three. The sooner a child receives autism support services such as behavioral interventions, occupational therapy, and speech therapy, the better chances that child has to thrive – even into adulthood.
‘Interventions initiated before three years of age may have a greater positive impact than those begun after the age of five years,’ a study published in the American Academy of Pediatrics reported.”
You can read more about this recent medical breakthrough and see if the Clarifi ASD test is right for by visiting www.todaybiotech.com.
Although myHana Autism is not a partner of Clarifi ASD, we do support the push to expand the scope of care that is made available to parents and families with those on the autism spectrum.
We believe that early intervention is key to an independent future and that is why myHana is committed to providing a comprehensive, professionally developed, suite of solutions for parents and families.
We also believe in access to effective, researched based treatment and protocols. It’s never too early to get started!
The myHana Team